Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

United Therapeutic (UTHR)

United Therapeutic (UTHR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

United Therapeutic 1000 SPRING ST SILVER SPRING MD 20910 USA

www.unither.com Employees: 1,168 P: 301-608-9292 F: 301-608-9291

Description:

United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH): Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; also sold by Eli Lilly as Cialis for erectile dysfunction) tablets.

Key Statistics

Overview:

Market Capitalization, $K 16,265,512
Enterprise Value, $K 15,757,812
Shares Outstanding, K 44,645
Annual Sales, $ 2,328 M
Annual Net Income, $ 984,800 K
Last Quarter Sales, $ 748,900 K
Last Quarter Net Income, $ 309,100 K
EBIT, $ 1,279 M
EBITDA, $ 1,333 M
60-Month Beta 0.56
% of Insider Shareholders 11.90%
% of Institutional Shareholders 94.08%
Float, K 39,332
% Float 88.10%
Short Volume Ratio 0.71

Growth:

1-Year Return 59.10%
3-Year Return 88.15%
5-Year Return 294.89%
5-Year Revenue Growth 42.98%
5-Year Earnings Growth 47.95%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 6.39 on 10/30/24
Next Earnings Date N/A
Earnings Per Share ttm 22.77
EPS Growth vs. Prev Qtr 9.23%
EPS Growth vs. Prev Year 18.77%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 2-1 on 09/23/09

UTHR Ratios

Ratio
Price/Earnings ttm 15.84
Price/Earnings forward 14.31
Price/Earnings to Growth 1.05
Return-on-Equity % 19.22%
Return-on-Assets % 16.15%
Profit Margin % 42.31%
Debt/Equity 0.07
Price/Sales 6.92
Price/Cash Flow 16.26
Price/Book 2.63
Book Value/Share 136.64
Interest Coverage 22.49
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar